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pleted every 6 months, as well as the Subjective Side Effect Rating Scale, assessing 
patient distress over extrapyramidal symptoms, weight gain, sedation and sexual 
dysfunction over the past seven days. A random-effects regression analysis was 
used to estimate the impact of these adverse events on utilities with adjustment 
on disease severity and other potential confounding factors. Results: Our sample 
consisted in 1208 patients with schizophrenia. At baseline, the mean EQ-5D utility 
was 0.73 (0.28), 57.7% of patients reported extrapyramidal symptoms, 46.2% weight 
gain, 46.5% sedation and 27.8% sexual dysfunction. The regression model showed 
that extrapyramidal symptoms, weight gain, sedation and sexual dysfunction were 
associated with reductions in utility of 0.054 (0.008), 0.018 (0.008), 0.021 (0.008) and 
0.032 (0.011) points, respectively. ConClusions: This study shows that side effects 
are associated with significant decrements in EQ-5D utility, especially extrapyrami-
dal symptoms. Additionally, adverse events may have an indirect negative impact 
on quality of life, since they may be associated with reduced treatment adherence, 
and therefore reduced treatment effectiveness.
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THe associaTion beTween residual syMPToMs of dePression wiTH 
MenTal and PHysical qualiTy of life in PaTienTs wHo Have been 
TreaTed wiTH anTidePressanT MedicaTions
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objeCtives: Examine the association between residual symptoms of depression 
(depressive symptoms still present after 3 months of antidepressant treatment) 
and patient reported mental and physical quality of life. Methods: A subset of 
patients from the 2012 National Health and Wellness survey (n = 71,157), an annual 
general health survey of US adults, was used in this analysis. Inclusion criteria 
were a diagnosis of depression and treatment with an antidepressant medication 
for at least 3 months (n = 5,354). Residual symptoms were measured via the 9-item 
Personal Health Questionnaire (PHQ-9) depression scale and quality of life was 
measured via the SF-36v2 mental and physical component summary scores (MCS 
and PCS). Inter-relationships among symptoms were assessed using Pearson cor-
relations, and Ordinary Least Squares (OLS) regression was used for MCS and PCS 
analyses. Results: The most common residual symptoms were fatigue (49.6%; 
“Feeling tired or having little energy”) and sleep problems (42.8%; “Trouble falling 
or staying asleep, or sleeping too much”). All residual symptoms were more strongly 
correlated with MCS scores (r = -.37 to -.60) compared with PCS scores (r = -.06 to 
-.26) (p< .01). In the OLS regression models, anhedonia (“Little interest or pleasure in 
doing things”) and sadness (“Feeling down, depressed, or hopeless”) held the strong-
est associations with lower MCS scores (p< .001), whereas fatigue held the strongest 
association with lower PCS scores (p< .001) after controlling for other residual symp-
toms. ConClusions: Residual symptoms of depression persist despite adequate 
duration of antidepressant treatment and are associated with poorer quality of life. 
Anhedonia and sadness were most strongly associated with lower mental quality 
of life while fatigue was most strongly associated with lower physical quality of life.
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in biPolar dePression: direcT effecTs and indirecT effecTs MediaTed 
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objeCtives: The efficacy of lurasidone in reducing depression symptoms and 
improving functioning among patients with bipolar depression has been previ-
ously demonstrated. This analysis examines the direct and indirect effect (mediated 
through improvement in depression symptoms) of lurasidone in improving patient 
functioning. Methods: Data from a 6-week, double-blind, placebo-controlled trial 
assessing the effect of treatment [lurasidone (20–60 mg or 80-120 mg) versus pla-
cebo] in bipolar depression was used. Patient functioning was measured using a vali-
dated patient reported outcomes scale, Sheehan Disability Scale (SDS), that assessed 
functioning in work/school, family, and social life (higher scores indicate greater 
disability). Depression symptoms were measured using the 10-item Montgomery-
Asberg Depression Rating Scale (MADRS; higher scores indicate greater severity). 
Path analyses evaluated total effect (β 1), as well as the indirect effect (β 2*β 3) and 
direct effect (β 4) of treatment on SDS change, using standardized beta path coef-
ficients and baseline scores as covariates. The direct effect of treatment on SDS 
change and indirect effects accounting for mediation through MADRS change was 
examined for statistical significance and magnitude. Results: Path analyses (n 
= 258) revealed a moderate total effect for treatment predicting improvement in SDS 
score (β 1= -0.40, p= 0.001). Treatment predicted improvement in MADRS (β 2= -0.33, 
p= 0.009), which subsequently predicted improvement in SDS (β 3= 0.70, p< 0.001; 
indirect effect = -0.23). The direct effect was small yet significant (β 4= -0.17, p= 0.04), 
indicating partial mediation. Indirect and direct effects accounted for 57% and 43% 
of the total effect, respectively. The full mediation model with indirect and direct 
effects explained 61.7% of the variation in the change in SDS scores. ConClusions: 
These analyses show that improvement in patient functioning among patients 
on lurasidone was largely mediated through reduction in depression symptoms. 
Lurasidone also had a small but statistically significant direct effect in improving 
patient functioning that was independent of improvements in depression within 
a 6-week study duration.
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objeCtives: This study aimed to determine the validity (construct, known-
groups), reliability (internal consistency), and floor and ceiling effects of the 12 
ratio (OR): 9.42; 95% confidence interval (CI): 8.55-10.39), female sex (OR: 1.11; 95%CI: 
1.01-1.22), age 55-64 (OR: 1.26; 95%CI: 1.09-1.46) relative to age 25-34, and Hispanic 
(OR: 1.37; 95%CI: 1.05-1.81) relative to white. An incremental $10K in BY inpatient 
admission cost was also associated with greater likelihood of success (OR: 1.11; 
95%CI: 1.08-1.15). Accounting for baseline differences between treatment cohorts 
using IPW, PP use was associated with a 26% increase in the likelihood of continuity 
achievement compared to other AP use (OR: 1.26; 95%CI: 1.14-1.39). ConClusions: 
Baseline factors associated with better performance on the HEDIS Continuity of AP 
Medications measure were prior year adherence, use of PP therapy, higher inpatient 
costs, older age, female gender, and Hispanic ethnicity.
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iMPacT of aTyPical anTiPsycHoTics use on long acTing sTiMulanTs 
PersisTence aMong cHildren and adolescenTs wiTH aTTenTion 
deficiT HyPeracTiviTy disorder
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objeCtives: Pediatric Attention Deficit/Hyperactivity Disorder (ADHD) patients are 
usually prescribed combination of psychotropic agents. This study looked at the 
impact of atypical antipsychotic (AAP) use on long acting stimulant (LAS) persis-
tence in children and adolescents with ADHD. Methods: This study used 4 years 
(January 2004 to December 2007) of IMS LifeLink™ claims data involving 6-16 years 
old youths with ADHD and at least 1 LAS prescription between July 2004 to December 
2006 and continuous eligibility 6 months before and 1 years after the index LAS pre-
scription. Persistence was measured by summing the total number of days a patient 
remained on the index LAS from the index prescription date with allowable gap of 
no more than 30 days. Multivariate Cox proportional hazards regression was used 
to examine the impact of concomitant atypical antipsychotic use on persistence of 
stimulants. Results: The study cohort consisted of 39,981 subjects. Of these, 1,560 
(3.90%) received LAS and AAP polypharmacy and the rest 38,421 (96.10%) received 
LAS monotherapy. Bivariate analyses revealed that concomitant users had longer 
persistence (by 71 days) than the stimulant alone users. Cox proportional hazards 
regression revealed that concomitant atypical antipsychotic use improved LAS per-
sistence by 15% (HR= 0.85, CI= 0.76-0.94) in comparison to the non-users among LAS 
recipients. Other factors such as age, region, season, coexisting mental health condi-
tions, use of co-medications, and general mental health status influenced the LAS 
treatment persistence among children and adolescents with ADHD. ConClusions: 
Use of atypical antipsychotics improved LAS treatment persistence in children and 
adolescents with ADHD. Various patient, clinical and treatment factors were associ-
ated with the LAS treatment persistence in ADHD youths. Understanding of these 
factors can help to improve persistence to LAS treatment.
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objeCtives: The aim of this study was to determine the impact of antidepressant 
adherence on health-related quality of life and life satisfaction in a representative 
community sample of older adults. Methods: The data were obtained from the 
ESA (Étude sur la Santé mentale des Aînés) Services study that included a large 
sample of older adults (n= 1809) aged 65 years and over who consulted and were 
recruited in a primary care practices. HRQOL was measured using the EuroQOL-5D 
which assessed utility values, from the general population perspective and the 
EQ-Visual Analog Scale (EQ-VAS) was used to measure self-reported health sta-
tus from the patient perspective. The CASP was used to measure life satisfaction. 
Common mental disorders were based on DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition) criteria. Antidepressant use was obtained from 
administrative databases. A 4 level dummy variable was constructed to consider the 
presence of depression/anxiety (MD) and antidepressant use (MD X AD). Adherence 
to antidepressant was measured using the medication possession ratio (MPR ≥ 
80%). Multivariate linear regression models were used to study HRQOL and life 
satisfaction as a function of depression/anxiety X antidepressant use (MD X AD) 
controlling for antidepressant use, the presence of chronic and physical disorders 
and other socio-demographic factors. Results: HRQOL measured by the EuroQOL 
was significantly associated with age, cognitive impairment and the presence of 
depression. Self-reported health status measured by the EQ-VAS was associated 
with age, number of chronic illnesses, cognitive impairment. The CASP was associ-
ated with age, and PTSD. Antidepressant use was associated with a lower HRQOL 
and a lower life satisfaction. ConClusions: The study showed that the determi-
nants associated with HRQOL and life satisfaction from the patient and general 
population perspective differs. Future studies should focus on determining other 
factors that influence HRQOL and life satisfaction in older adults.
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uTiliTy decreMenTs associaTed wiTH TreaTMenT-relaTed adverse 
evenTs in scHizoPHrenia
Millier A.1, Amri I.2, Toumi M.3
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objeCtives: Several studies have estimated health state utilities for patients 
with schizophrenia according to disease stage. However, the quality of life of these 
patients is also largely dependent on treatment-related adverse events, and there 
is paucity of data on utilities associated with those adverse events. The objective 
of this study was to estimate utility decrements associated with treatment-related 
adverse events in patients with schizophrenia, using data from an observational 
study. Methods: We used data from EuroSC, a multicenter 2-year cohort study 
conducted in France, England and Germany. The EQ-5D questionnaire was com-
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objeCtives: Binge Eating Disorder (BED) recently moved, with slight modifica-
tion, from the DSM-IV appendix to a fully recognized disorder in DSM-5. There 
is limited information on the impact of BED on productivity and social function-
ing. One cross-national epidemiological study reported BED was associated with 
an increased number of days of role impairment. We report here the associations 
of DSM-5 defined BED, with work productivity and functional impairment in the 
work/school, social and family life domains. Methods: An Internet survey of a 
representative sample of US adults, conducted in fall, 2013, included questions 
related to demographics, general health, psychiatric comorbidities, assessment for 
DSM-5 criteria for BED, the Work Productivity and Activity Impairment questionnaire 
(WPAI) and the Sheehan Disability Scale (SDS). SDS and WPAI were compared (BED 
vs no BED groups) via ANOVA. Results: Among 22,397 respondents, 344 (1.5%) 
participants (242 women and 102 men) met full DSM-5 criteria for BED, 1,616 (7.2%) 
reported overeating with loss of control but not meeting DSM-V criteria for BED. 
The remainder of the respondents, 20,437 (91.3%), may have reported overeating but 
no other BED symptoms. Relative to those with no BED, those with BED had higher 
mean[SD] impairment on SDS work/school (3.86[3.62]) vs 1.01[2.21], p< 0.001), social 
life (5.29[3.49] vs 1.22[2.33], p< 0.001) and home/family life (4.89[3.44] vs 1.18[2.26], 
p< 0.001). As measured by WPAI, those with BED, compared to those in the no BED 
group, had higher mean[SD] scores for absenteeism (9.59[19.97] vs 2.90[12.95]), 
presenteeism (30.00[31.64] vs 10.86[20.07]), work productivity loss (33.19[33.85] vs 
12.60[23.22]), and activity impairment (43.52[34.36] vs 19.94[27.22]) respectively 
(p< 0.001 for all). ConClusions: This is the first large population study to examine 
the association of BED, using DSM-5 criteria, with work productivity and daily func-
tioning. Results suggest that those with BED experience considerable impairment 
in functioning and work productivity relative to those without BED.
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do dePressed PaTienTs on adjuncTive aTyPical anTiPsycHoTics 
deMonsTraTe a beTTer qualiTy of life coMPared To THose on 
anTidePressanTs only? (a coMParaTive cross-secTional sTudy of a 
naTionally rePresenTaTive saMPle of THe uniTed sTaTes PoPulaTion)
Alruthia Y.S., Hong S.H., Solomon D.K.
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objeCtives: The adjunctive use of some atypical antipsychotics (AAPs) has shown 
to provide some benefits in improving the depressive symptoms in patients with 
treatment-resistant depression. However, little is known about the impact of these 
agents on patients’ health-related quality of life (HRQoL). Methods: Patients 
with self-reported depression (ICD-9: 296, 300, and 311), and have used the given 
AAPs and/or antidepressants for at least a year, were identified in the Medical 
Expenditure Panel Survey (MEPS) of 2008-2011. The patients were classified into 
users of adjunctive AAPs (i.e., antidepressants plus AAPs) and users of antidepres-
sants only. The AAPs were identified based on documented evidence, and included 
risperidone, aripiprazole, quetiapine, olanzapine, and ziprasidone. Multivariate 
linear regression analyses were conducted to determine whether the utilization 
of AAPs was associated with the Physical Component Summary-12 (PCS12) or with 
Mental Component Summary-12 (MCS-12) of HRQoL measure. Socio-demographics, 
Charlson Comorbidity Index, psychotherapy (i.e., cognitive behavioral therapy), 
Patient Health Questionniare-2 (PHQ-2) scores, and the number of prescription 
medications associated with depression were controlled. Results: A total of 3,638 
participants reported to have depression and to have used the given AAPs and/or 
antidepressants for at least a year during the period of 2008-2011 (306 on AAPs vs. 
3,332 on antidepressants only). The study subjects were ≥ 18 years, predominately 
White (91.9%) and female (71%). The adjunctive AAPs utilization was not associated 
with higher scores in the PCS-12 (β = 1.455, 95% CI = − 0.1366-3.0459, p = 0.0729). 
Rather, it was negatively associated with the MCS-12 scores (β = − 1.549, 95% CI 
= − 3.0171-− 0.0822, p = 0.0386). ConClusions: The adjunctive utilization of AAPs 
was not associated with higher scores of HRQoL. Future studies should examine 
whether poor mental scores of HRQoL have occurred from lower medication adher-
ence to AAPs or from lower baseline HRQoL scores among users of adjunctive AAPs.
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anTicHolinergic drug use and HealTH relaTed qualiTy of life 
(Hrqol) in THe elderly wiTH deMenTia
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objeCtives: People with dementia are sensitive to cognitive side effects of 
anticholinergic drugs and this may adversely affect their Health Related Quality of 
Life (HRQoL). The study examined the association between the use of drugs with 
anticholinergic properties and HRQoL among community-dwelling elderly dementia 
patients. Methods: This was a retrospective longitudinal cohort study involving 
elderly (age> = 65 years) patients with a diagnosis of dementia, using data from 
Medical Expenditure Panel Survey (MEPS) panels 9 to 13. Each panel consisted of 
five rounds which spanned over the period of two years. Patients who used anticho-
linergic drugs in round 1 or 2 were excluded. Anticholinergic drug exposure was 
measured in rounds 3 and 4 using Anticholinergic Drug Scale (ADS), an ordinal scale 
that rates anticholinergic drugs into levels 0 - 3 in increasing order of anticholinergic 
potency. The outcomes of interest were Physical Component Score (PCS) and Mental 
Component Score (MCS) based on Short-Form 12 (SF-12) health survey, measured 
in round 4. Two separate multiple linear regressions analyses were performed to 
determine the association of anticholinergic drugs with PCS and MCS while adjust-
ing for sociodemographic variables and baseline HRQoL measures. Results: The 
study included 112 patients, of which, 15.18% used anticholinergic drugs. Majority 
of the study participants were between ages of 65-79 (53%), females (57%), and with 
poor or low family income (65%). After controlling for sociodemographic and base-
line characteristics, anticholinergic drug use was significantly associated with 5.75 
units reduction in PCS (p-value: 0.01) whereas no association was found between 
anticholinergic use and MCS. Baseline HRQoL measures were found significant in 
both models. ConClusions: Anticholinergic medications were associated with 
item Medical Outcomes Study Short-Form Health Survey version 2 (SF-12v2) among 
adults with autism. Methods: Study data was collected using an online survey 
(Qualtrics software system) of 291 adults with autism registered with the Interactive 
Autism Network (IAN). Using confirmatory factor analysis, construct validity of the 
SF-12v2 was examined by comparing model fits across four different iterations of 
the SF-12v2 two-factor structure. Known-groups validity was assessed by compar-
ing SF-12v2 physical component summary (PCS) and mental component summary 
(MCS) score by autism severity. Internal consistency reliability was determined using 
Cronbach’s alpha. Floor and ceiling effects were assessed based on the percentage of 
participants scoring the lowest and highest possible score, respectively. Results: 
Results from CFA indicated an adequate fit with the data for the two-factor SF-12v2 
model with minor modifications. As per known-groups validity, the SF-12v2 MCS 
domain adequately distinguished adults with autism by severity, with higher MCS 
score observed among adults with low autism severity as compared to those with 
high autism severity. However, contrary results were observed for the PCS domain. 
High internal consistency reliability was observed for the PCS domain (Cronbach’s 
alpha 0.87), MCS domain (Cronbach’s alpha 0.73), and overall instrument (Cronbach’s 
alpha 0.84). There were no floor and ceiling effects. ConClusions: The SF-12v2 had 
good construct validity, and the factor structure fit well with the data. The known-
groups validity of the SF-12v2 warrants further investigation in this population. 
Reliability of the instrument was good, and there were no floor and ceiling effects. 
Overall, SF-12v2 had adequate psychometric properties among adults with autism.
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objeCtives: To assess the content validity and patient interpretation of the Self-
Reported Misuse, Abuse and Diversion (SR-MAD) of Prescription (Rx) Opioids instru-
ment. Methods: A cross-sectional, qualitative study was conducted in patients 
with chronic or acute pain. Patients were recruited from 3 clinical sites based on 
three patient groups (opioid naïve, known opioid abusers, and chronic opioid non-
abusers) to participate in a one-on-one cognitive interview. Patients completed the 
SR-MAD instrument via web-administration and then participated in an in-depth 
discussion following a semi-structured interview guide to assess the patient’s 
understanding of the questionnaire. Descriptive statistics and content analysis were 
performed. Results: Thirty-seven patients were interviewed: 11 opioid naïve; 13 
known abusers; and 13 non-abusers. Mean age was 55 ± 13.5 years (range 26 to 84); 
33 patients (89%) experienced chronic pain, three (8%) experienced acute pain, and 
one (3%) experienced both chronic and acute pain. Overall, most patients (n= 31, 84%) 
demonstrated a comprehensive understanding of the questionnaire’s content and 
reported the SR-MAD was easy to complete via web-administration. The majority of 
patients (n= 28, 76%) reported they were truthful when completing the questionnaire 
and most (n= 22, 59%) said they were comfortable completing the questionnaire 
using a secure internet site. Although some patients (n= 15, 41% [opioid naïve n= 5, 
known abusers n= 7, and non-abusers n= 3]) reported there were questions about 
opioid misuse that were not applicable to them, they all understood what was 
being asked and thought the questions would be relevant if they were abusing pain 
medication. Eight patients (known abusers n= 4, non-abusers n= 1, opioid naïve n= 3) 
reported they were not comfortable answering the SR-MAD honestly in a clinic/doc-
tor’s office. ConClusions: The SR-MAD was developed based on patient input and 
addresses opioid abuse, misuse, and diversion. Additional interviews with aberrant 
opioid abusers are underway to further examine the content validity of the SR-MAD.
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objeCtives: The purpose of this study was to determine the predictors of quality of 
life (QOL) among adults with autism. A modified version of Wilson and Cleary’s QOL 
conceptual model was used to study the relationship between autism severity, coping, 
functional independence, social support and QOL in adults with autism. Methods: 
A cross-sectional, descriptive quantitative design was utilized for this study. An inter-
net-based survey using Qualtrics online software system was administered to adults 
with autism enrolled with the Interactive Autism Network (IAN). Among these adults, 
those who were: 1) aged 18 years and above; and 2) capable of self-reporting with little 
or no proxy help were identified and approached for participation. Structural equation 
modeling (SEM) was used to identify the inter-relationship among study variables 
and to identify the factors influencing QOL among adults with autism. Results: 
The survey sample included 262 adults with autism. Results from the SEM analysis 
revealed the modified Wilson and Cleary’s QOL model tested in the study to have an 
adequate fit (chi-square= 49.75, df= 17; RMSEA= 0.88; CFI= 0.95). Significant correlations 
among coping, functional independence, social support and QOL domains (p< 0.05) 
were observed. Study results depicted autism severity, maladaptive coping, appraisal 
social support and functional independence as significant predictors of physical and 
environment QOL. Autism severity had a significant (p< 0.05) negative impact on 
physical, psychological and environment QOL. Higher degree of social support and 
adaptive coping were found to have a positive influence on QOL. ConClusions: 
Modifiable variables including social support and coping were found to influence QOL 
among adults with autism. Physicians and other health care professionals involved in 
the management of autism among these adults should consider these factors when 
designing treatment intervention strategies.
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